Cryptosporidium parvum (Cp) is a potential biowarfare agent and major cause of diarrhea and malnutrition. This protozoan parasite relies on inosine 5′-monophosphate dehydrogenase (IMPDH) for the production of guanine nucleotides. A CpIMPDH-selective N-aryl-3,4-dihydro-3-methyl-4-oxo-1-phthalazineacetamide inhibitor was previously identified in a high throughput screening campaign. Herein we report a structure-activity relationship study for the phthalazinonebased series that resulted in the discovery of benzofuranamide analogs that exhibit low nanomolar inhibition of CpIMPDH. In addition, the antiparasitic activity of select analogs in a Toxoplasma gondii model of C. parvum infection is also presented.
(IMPDH) for the production of guanine nucleotides [2] [3] [4] . This enzyme catalyzes the oxidation of IMP to XMP with the production of NADH as outlined in Scheme 1 5 . Curiously, the Cryptosporidium IMPDH gene appears to have been obtained from an ε-proteobacterium via horizontal gene transfer 6 , and is structurally distinct from the host ortholog (the C. parvum and C. hominis enzymes are identical and will be denoted as CpIMPDH). Consequently, CpIMPDH displays unique enzymatic properties compared with the host counterparts 7 .
A previously reported high throughput screening (HTS) campaign identified several structurally distinct classes of selective CpIMPDH inhibitors that bind to the NAD site 8, 9 .
Structure-activity relationship studies of triazole 10 , benzimidazole 9, 11 and urea 12 CpIMPDH inhibitors, exemplified by A110, C64, C97 and P96, respectively, have also now been reported (Figure 1 ). In addition, a co-crystal structure of the benzimidazole inhibitor C64 with CpIMPDH demonstrated a unique binding mode compared to inhibitors bound to human IMPDH 9 . The phthalazinone-based inhibitor 1 was also identified by HTS, with moderate potency (IC 50 = 5.4 μM) and good selectivity (IC 50 > 50 μM versus both human IMPDH1 and IMPDH2) 8 . Compound 1 (50 μM) did not display antiparasitic activity 8 . Herein we report a structure-activity relationship study of 1, and the antiparasitic activity of select analogs in a T. gondii model of C. parvum infection.
Compound 1 and its analogs were prepared following a four-step sequence as depicted in Scheme 2 beginning with the Wittig olefination of phthalic anhydride, 2, in the presence of carbethoxymethylidenetriphenylphosphorane in chloroform to produce (E)-ethyl-2-(3-oxoisobenzofuran-1(3H)-ylidene)acetate, 3. Addition of hydrazines in refluxing ethanol generated the phthalazinone acetoesters 4. Hydrolysis of the esters produced phthalazinone acetic acids 5 13, 14 . Finally, coupling of the acetic acid moiety with various aromatic amines in DMSO afforded 6.
The synthesized derivatives were evaluated for CpIMPDH inhibition using an assay that monitored the production of NADH in the presence of varying inhibitor concentrations 10 . In order to evaluate the effects of non-specific binding, inhibition was also determined in the presence of 0.05% fatty acid free bovine serum albumin (BSA). None of the compounds inhibited human IMPDH2 (IC 50 > 5 μM).
Inhibitor 1 exhibited an IC 50 of 1.0 μM upon resynthesis. Gratifyingly, the activity was retained in the presence of 0.05% BSA (IC 50 = 970 nM) as shown in Table 1 . However, moving the electron donating group to the 2-or 3-position resulted in loss of activity (7 and 10). Replacing the 4-OMe with a variety of other electron donating substituents (11 -14) was also detrimental. Likewise, replacing the phenyl with an amine (8) or alkyl group (9) or inserting a methylene between the benzene and amide nitrogen atom (15) was not tolerated. Replacement of the electron donating group at the 4-position with electron withdrawing groups improved potency. For example, the 4-chloro and 4-bromo analogs (16 and 17) demonstrated IC 50 values of 230 and 130 nM, respectively. However, other electron withdrawing groups (18 -21) generally were not as well tolerated. Also, transposition of the chlorine from the 4-position to the 3-position (23) resulted in loss of activity. Di-substitution at the 3,4-positions with chlorine and bromine atoms (24 and 25) resulted in increased potency. Furthermore, other 3,4-di-substituted analogs with either an electron-donating or an electron-withdrawing group at the 3-position were also active. Interestingly, in a number of cases substituents at the 3-position that alone were not tolerated when combined with electron withdrawing groups (especially Cl or Br) at the 4-position resulted in potent CpIMPDH inhibitors (e.g. 26, 27 and 37). However, transposition of the substituents from the 3-position to the 2-position (39 -42) resulted in poor inhibitors. In addition, several other di-and tri-substitutions (43 -46) were also detrimental. Encouraged by the results of 3,4-disubstitution, the 2-naphthyl analog 47 was prepared and demonstrated an IC 50 of 63 nM. Similar increases in CpIMPDH activity by introduction of 3,4-disubstitution or incorporation of 2-naphthylene had also been observed in the structure-activity relationship studies resulting in A110 and C97 10, 11 . Finally, analogs that lack methylation of the phthalazinone nitrogen atom (48 and 49) were found to be active indicating that this substituent is not necessary for CpIMPDH inhibitory activity.
Inspired by the results with 47, a variety of fused heterocycles were explored as replacements of the 2-naphthylene (Table 2) . Although the 5-benzofuranyl analog 50 had reduced activity and the 5-benzoxazolyl analog 51 was inactive, the 2-methyl-5-benzofuranyl derivative 52 retained activity with an IC 50 of 64 nM. Furthermore, incorporation of an additional ring (53) resulted in enhanced potency. Unsaturation of the ring further increased activity with 54 demonstrating an IC 50 of 4 nM. However, the regioisomer 55 and two carbazoles 56 and 57 were not active.
Compounds with IC 50 values less than 30 nM were candidates for evaluation of antiparasitic activity in a Toxoplasma gondii model of C. parvum infection 15 . In this model, the endogenous T. gondii IMPDH and hypoxanthine-guanine-xanthine phosphoribosyltransferase genes have been knocked out and the CpIMPDH gene inserted to create T. gondii/CpIMPDH, a model parasite that relies on CpIMPDH for the production of guanine nucleotides. Both wild-type and T. gondii/CpIMPDH were cultured in human foreskin fibroblasts immortalized with hTERT, so this assay also reports on host cell toxicity. Compounds 26, 27, 53 and 54 all displayed sub-micromolar activity against T. gondii/CpIMPDH (Table 3) . However, only 27 displayed selectivity • 30 versus the wildtype strain, strongly indicating that antiparasitic activity results from the inhibition of CpIMPDH.
The inhibition of CpIMPDH by compound 27 was characterized further. Whereas compound 1 is a mixed inhibitor of CpIMPDH with respect to NAD + (K is = 1.8 μM, K ii = 7μM) 8 , 27 is a pure noncompetitive inhibitor (K is = K ii = 3.4 ± 0.2 nM; Figure 2 ).
Compound 27 displayed good stability in mouse liver microsomes (T 1/2 = 79 min). This compound was advanced into the IL12 knockout mouse model of C. parvum infection [16] [17] [18] [19] . Disappointingly, no antiparasitic activity was observed with once per day oral dosing of 27 (250 mg/kg) for seven days. It may be that alternative dosing regimes or modifications in formulations could improve efficacy in vivo. Additional optimization of pharmacokinetic properties may also be necessary for this compound series in order to achieve in vivo efficacy.
In conclusion, a SAR study of phthalazinone-based CpIMPDH inhibitors revealed that expansion of the aniline ring could increase inhibitory activity, while maintaining selectivity relative to the human orthologs. The phthalazinone-based CpIMPDH inhibitors described herein could serve as lead compounds for the development of effective treatments of cryptosporidiosis as well as useful molecular probes for studying Cryptosporidium parasites.
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